BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26984744)

  • 21. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
    Nobusawa S; Hirato J; Yokoo H
    Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins in human ependymoma relates to tumor location, WHO grade, and patient age.
    Yi W; Haapasalo H; Holmlund C; Järvelä S; Raheem O; Bergenheim AT; Hedman H; Henriksson R
    Clin Neuropathol; 2009; 28(1):21-7. PubMed ID: 19216216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation.
    Ozawa T; Kaneko S; Szulzewsky F; Qiao Z; Takadera M; Narita Y; Kondo T; Holland EC; Hamamoto R; Ichimura K
    Acta Neuropathol Commun; 2021 Mar; 9(1):36. PubMed ID: 33685520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma.
    Cachia D; Wani K; Penas-Prado M; Olar A; McCutcheon IE; Benjamin RS; Armstrong TS; Gilbert MR; Aldape KD
    Brain Tumor Pathol; 2015 Apr; 32(2):105-11. PubMed ID: 25388523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
    Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J
    J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features.
    Andreiuolo F; Varlet P; Tauziède-Espariat A; Jünger ST; Dörner E; Dreschmann V; Kuchelmeister K; Waha A; Haberler C; Slavc I; Corbacioglu S; Riemenschneider MJ; Leipold A; Rüdiger T; Körholz D; Acker T; Russo A; Faber J; Sommer C; Armbrust S; Rose M; Erdlenbruch B; Hans VH; Bernbeck B; Schneider D; Lorenzen J; Ebinger M; Handgretinger R; Neumann M; van Buiren M; Prinz M; Roganovic J; Jakovcevic A; Park SH; Grill J; Puget S; Messing-Jünger M; Reinhard H; Bergmann M; Hattingen E; Pietsch T
    Brain Pathol; 2019 Mar; 29(2):205-216. PubMed ID: 30246434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
    Godfraind C; Kaczmarska JM; Kocak M; Dalton J; Wright KD; Sanford RA; Boop FA; Gajjar A; Merchant TE; Ellison DW
    Acta Neuropathol; 2012 Aug; 124(2):247-57. PubMed ID: 22526017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C11orf95-RELA fusion present in a primary intracranial extra-axial ependymoma: Report of a case with literature review.
    Nambirajan A; Malgulwar PB; Sharma MC; Singh A; Pathak P; Satyarthee GD; Garg A
    Neuropathology; 2016 Oct; 36(5):490-495. PubMed ID: 27121356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.
    Chen C; Chen L; Yao Y; Qin Z; Chen H
    J Neurooncol; 2016 Mar; 127(1):43-52. PubMed ID: 26615563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Supratentorial cortical ependymoma: A systematic literature review and case illustration.
    Cuoco JA; Strohman AC; Stopa BM; Stump MS; Entwistle JJ; Witcher MR; Olasunkanmi AL
    Rare Tumors; 2022; 14():20363613221112432. PubMed ID: 35836750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
    Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
    Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracranial ependymomas in children.
    Undjian S; Marinov M
    Childs Nerv Syst; 1990 May; 6(3):131-4. PubMed ID: 2357709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.
    Witt H; Gramatzki D; Hentschel B; Pajtler KW; Felsberg J; Schackert G; Löffler M; Capper D; Sahm F; Sill M; von Deimling A; Kool M; Herrlinger U; Westphal M; Pietsch T; Reifenberger G; Pfister SM; Tonn JC; Weller M;
    Neuro Oncol; 2018 Nov; 20(12):1616-1624. PubMed ID: 30053291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ependymal tumors in childhood.
    Agaoglu FY; Ayan I; Dizdar Y; Kebudi R; Gorgun O; Darendeliler E
    Pediatr Blood Cancer; 2005 Sep; 45(3):298-303. PubMed ID: 15770637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. epi-Aszonalenin B from Aspergillus novofumigatus inhibits NF-κB activity induced by ZFTA-RELA fusion protein that drives ependymoma.
    Ishikawa K; Ishii M; Yaguchi T; Katada T; Ichinose K; Ohata S
    Biochem Biophys Res Commun; 2022 Mar; 596():104-110. PubMed ID: 35131506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment results in patients with intracranial ependymomas.
    Boström A; Boström J; Hartmann W; Pietsch T; Feuss M; von Lehe M; Simon M
    Cent Eur Neurosurg; 2011 Aug; 72(3):127-32. PubMed ID: 21630189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nestin expression identifies ependymoma patients with poor outcome.
    Milde T; Hielscher T; Witt H; Kool M; Mack SC; Deubzer HE; Oehme I; Lodrini M; Benner A; Taylor MD; von Deimling A; Kulozik AE; Pfister SM; Witt O; Korshunov A
    Brain Pathol; 2012 Nov; 22(6):848-60. PubMed ID: 22568867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic results of eight patients with intracranial ependymomas].
    Sasajima T; Takahashi M; Kinouchi H; Suzuki A; Mizoi K
    No To Shinkei; 2003 Mar; 55(3):233-40. PubMed ID: 12728504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma.
    Zhu JJ; Jillette N; Li XN; Cheng AW; Lau CC
    Acta Neuropathol; 2020 Dec; 140(6):951-960. PubMed ID: 32909151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.